Inventisbio Co. Ltd. and Inventisbio LLC have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety potentially useful for the treatment of cancer.